Clinical trial
Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00014300 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00014300 |
|---|---|
| Title | Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme |
| Official title | Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | glufosfamide |
| Enrollment | 32 |
| Start date | Jan 1, 2001 |
| Primary completion | Sep 1, 2001 |
| First posted | Mar 17, 2004 |
| Last update posted | Sep 24, 2012 |
| Countries | Austria, France, Greece, Israel, Italy, Netherlands, Portugal, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: